160 related articles for article (PubMed ID: 37296430)
1. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Walsh EI; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM
BMC Health Serv Res; 2023 Jun; 23(1):610. PubMed ID: 37296430
[TBL] [Abstract][Full Text] [Related]
2. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract][Full Text] [Related]
3. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Turner EL; Metcalfe C; Donovan JL; Noble S; Sterne JA; Lane JA; Avery KN; Down L; Walsh E; Davis M; Ben-Shlomo Y; Oliver SE; Evans S; Brindle P; Williams NJ; Hughes LJ; Hill EM; Davies C; Ng SY; Neal DE; Hamdy FC; Martin RM;
Br J Cancer; 2014 Jun; 110(12):2829-36. PubMed ID: 24867688
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017.
Clift AK; Coupland CA; Hippisley-Cox J
Br J Gen Pract; 2021; 71(703):e157-e165. PubMed ID: 33431381
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
6. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
[TBL] [Abstract][Full Text] [Related]
7. Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
Thorn JC; Turner EL; Hounsome L; Walsh E; Down L; Verne J; Donovan JL; Neal DE; Hamdy FC; Martin RM; Noble SM;
BMJ Open; 2016 Apr; 6(4):e011063. PubMed ID: 27130167
[TBL] [Abstract][Full Text] [Related]
8. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
10. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
11. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
[TBL] [Abstract][Full Text] [Related]
14. Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
Williams NJ; Hill EM; Ng SY; Martin RM; Metcalfe C; Donovan JL; Evans S; Hughes LJ; Davies CF; Hamdy FC; Neal DE; Turner EL;
BMC Med Res Methodol; 2015 Jan; 15():6. PubMed ID: 25613468
[TBL] [Abstract][Full Text] [Related]
15. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study.
Clements A; Watson E; Rai T; Bukach C; Shine B; Austoker J
BMC Fam Pract; 2007 Jun; 8():35. PubMed ID: 17593306
[TBL] [Abstract][Full Text] [Related]
16. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
18. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
Brett J; Watson E; Hewitson P; Bukach C; Edwards A; Elwyn G; Austoker J
BMC Fam Pract; 2005 Jun; 6(1):24. PubMed ID: 15946386
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen testing rates and referral patterns from general practice data in England.
Moss S; Melia J; Sutton J; Mathews C; Kirby M
Int J Clin Pract; 2016 Apr; 70(4):312-8. PubMed ID: 26987766
[TBL] [Abstract][Full Text] [Related]
20. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
